According to the EoI document, applications should be submitted before June 17 through email. "The EoI submitted by industries will be scrutinised by a Technical Assessment Committee (TAC). Only up to 15 industries will be given ToT on their capabilities, technical hand holding capability of DRDO and on First Come First Served Basis," it said.
New Delhi [India], June 9 (ANI): The Defence Research and Development Organisation (DRDO), which developed 2 -Deoxy-D-Glucose (2-DG), a drug used for the treatment of COVID-19 patients, has called for Expression of Interest (EoI) to transfer the technology to Indian pharmaceutical industries for production.
The Defence Research and Development Organisation or DRDO, which developed 2-Deoxy-D-Glucose (2-DG), a drug used for treatment of COVID-19 patients, has called for Expression of Interest to transfer the technology to Indian pharmaceutical firms.
DRDO To Transfer Technology Of Anti-COVID Drug 2-DG To India Pharma Firms, Invites EoI
by Swarajya Staff - Jun 9, 2021 07:25 AM
DRDO Logo (Pic Via Wikipedia)
The Defence Research and Development Organisation (DRDO) has sought Expression of Interest (EoI) for transfer of technology for bulk manufacturing of the 2-Deoxy-D-Glucose (2-DG), a drug developed by the DRDO for treatment of Covid-19 patients.
The drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of the DRDO, in collaboration with Dr Reddy s Laboratories (DRL), Hyderabad.
2-DG is a glucose analogue, which has the 2-hydroxyl group replaced by hydrogen. The molecule is transported in cells by the glucose transporters on the cell membrane but it cannot undergo further glycolysis and act as inhibitor of glycolysis. Therefore, cells with higher glucose uptake, for example tumor cells, virally infected cells, inflammatory cells have also a higher uptake of 2-DG.